Tim McCarthy of ImmuPharma PLC (AIM:IMM) (LON:IMM) spoke to Proactive London after recently announcing a company overhaul aimed at saving £1.1m a year from 2022 and said he was preparing for advanced trials for his lead. active.
The reorganization will see ImmuPharma France SA and Ureka SAS merge into a single company, based in the company’s R&D center in Bordeaux, France.
Their main asset, Lupuzor, is being developed for the treatment of the autoimmune disease Lupus and ImmuPharma, in collaboration with its partner Avion Pharma, is preparing to introduce the drug in a phase III trial.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that nothing posted on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is…
In exchange for publishing services rendered by the Company on behalf of the persons named herein, including the promotion by the Company of in any Site Content, the Company shall receive from such issuer an annual cash sum…
FOR OUR FULL DISCLAIMER, CLICK HERE